|2.||Lymphedema (Milroy Disease)
|4.||Renal Cell Carcinoma (Grawitz Tumor)
|1.||Andreyev, H J N: 7 articles (06/2013 - 11/2003)|
|2.||Guido, Alessandra: 3 articles (12/2015 - 12/2012)|
|3.||Fuccio, Lorenzo: 3 articles (12/2015 - 12/2012)|
|4.||Bourhis, Jean: 3 articles (06/2011 - 10/2004)|
|5.||Tait, D: 3 articles (02/2006 - 11/2003)|
|6.||Blake, P: 3 articles (02/2006 - 11/2003)|
|7.||Kondo, Tsunenori: 2 articles (12/2014 - 05/2014)|
|8.||Omae, Kenji: 2 articles (12/2014 - 05/2014)|
|9.||Hashimoto, Yasunobu: 2 articles (12/2014 - 05/2014)|
|10.||Kodama, Yoshiki: 2 articles (12/2014 - 05/2014)|
|1.||Cytidine Diphosphate (CDP)IBA
06/01/2012 - "We performed a retrospective review of post-pelvic cancer LLL patients that were treated with a CDP program between January 2004 and March 2011. "
06/01/2012 - "The aim of this study was to estimate the efficacy of an intensive CDP program, as well as to identify the predictors associated with lymphedema severity and response to CDP in lower limb lymphedema (LLL) after pelvic cancer therapy. "
06/01/2012 - "The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of response to CDP in lower limb lymphedema (LLL) after pelvic cancer treatment."
|2.||ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA
06/01/1998 - "To evaluate the clinical and biologic safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer. "
06/01/1998 - "AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers."
01/01/1997 - "Fifteen histologically classified lymph nodes in six patients with known primary pelvic cancer (four prostate; one rectum; one uterus) were evaluated with T2-weighted fast spin-echo (FSE) and T2*-weighted gradient-echo (GRE) MRI at 1.5T 12 to 48 hours after intravenous administration of Combidex at a dose of 1.7 mg Fe/kg. Quantitative image evaluation was performed by comparing signal intensity of individual nodes on pre- and postcontrast images. "
|3.||Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric
|4.||Sucralfate (Carafate)FDA LinkGeneric
08/08/1991 - "Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer."
05/01/1997 - "The results of several studies indicate that sucralfate treatment especially during radiotherapy for pelvic cancer leads to a significant amelioration of clinical symptoms and morphological changes. "
06/01/1992 - "Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer."
06/01/1997 - "Clinical trials of intravesical sucralfate seem warranted in patients irradiated for pelvic cancer or with severe cystitis caused by cytotoxic drugs."
06/01/1992 - "Therefore, we investigated the possible effects of sucralfate, an aluminium hydroxide complex of sulfated sucrose used in the treatment of gastric ulcer, in preventing radiation-induced diarrhea and bowel discomfort in patients treated with curative intention for pelvic cancer with external radiotherapy. "
|5.||Amifostine (Ethyol)FDA LinkGeneric
12/01/2002 - "The few clinical trial data available on the use of amifostine in cervical cancer or pelvic cancer patients suggest benefit in reducing treatment toxicity. "
06/20/2011 - "Updated data from individual patients with non-small-cell lung cancer, head and neck squamous cell carcinoma, and pelvic cancer treated with radiotherapy or chemoradiotherapy and randomly assigned to amifostine or not were included. "
12/01/2002 - "In a randomized phase II trial comparing SC amifostine versus no amifostine in 140 patients undergoing radiation therapy for head and neck, thoracic, or pelvic cancers, amifostine treatment was associated with reductions in mucosal toxicity and delays in radiation therapy among the 19 patients with head and neck cancer, as well as in the thoracic and pelvic cancer groups. "
12/01/2003 - "The limited available data on the use of amifostine in patients with cervical or pelvic cancers indicate a benefit in reducing chemoradiation toxicity, although cisplatin regimens used in the early investigations in cervical cancer are no longer considered optimal. "
|6.||Enoxaparin (Lovenox)FDA LinkGeneric
03/01/2010 - "Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study."
03/01/2010 - "These favorable efficacy and safety data support the use of enoxaparin (20mg twice daily for 14 days started 24-36 hours after surgery) in Japanese patients undergoing abdominal or pelvic cancer surgery."
03/28/2002 - "We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin or placebo for another 21 days. "
03/28/2002 - "Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxaparin prophylaxis for one week."
|7.||Morphine (MS Contin)FDA LinkGeneric
10/01/1981 - "Clinical trials for abatement of intractable pelvic cancer pain were conducted in two patients, each electing surgical implantation of one of two indwelling catheter systems for administration of morphine into the spinal epidural space. "
05/01/1986 - "Since December 1984, the authors have used this totally implantable drug delivery system for continuous epidural morphine infusion in two patients who had been suffering from chronic pain caused by pelvic cancer associated with metastatic and/or invasive lesions: Case 1: a 61-year-old man with rectum cancer; and Case 2: a 44-year-old man with colon cancer. "
|8.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
10/01/2012 - "The only recommendation that has been upgraded is to extend prophylaxis with low molecular weight heparins (LMWH) for four weeks after abdominal or pelvic cancer surgery. "
04/01/2000 - "Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial."
|9.||tranilast (N 5')IBA
05/01/1999 - "Nineteen patients with proven primary abdominal or pelvic cancer (prostatic [n = 10]; colonic [n = 5]; endometrial [n = 1]; Merkel cell tumor [n = 1]; lymphoma [n = 1]; seminoma [n = 1]) were enrolled as part of our phase II and phase III clinical trials. "
11/01/2005 - "From november 2001 to august 2002, six patients received trastuzumab for metastatic transitional cell carcinoma of the bladder (n=5) or renal pelvic cancer (n=1). "
|10.||erbB-2 Receptor (Receptor, erbB 2)IBA
01/01/1995 - "An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs) of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterectomy. "
02/01/2014 - "Pelvic exenteration is highly radical surgery offering the only potential cure for locally advanced pelvic cancer. "
01/01/1996 - "Further studies are ongoing to evaluate the efficacy of such a neosphincter as continent system for bladder substitution after pelvic exenteration for pelvic cancers."
10/01/2014 - "This study aimed to analyze the morbidity and survival associated with pelvic exenteration involving sacrectomy for advanced pelvic cancers at a single institution. "
12/01/2011 - "The aim of this study is to establish the feasibility of the management of recurrent pelvic cancers by robot-assisted laparoscopy, and particularly the feasibility of robot-assisted laparoscopy anterior pelvic exenteration, from a single center series of seven patients. "
07/01/2015 - "Pelvic exenteration is used in the treatment of several pelvic cancers, including those of the rectum, uterus, and bladder. "
|2.||Drug Therapy (Chemotherapy)
03/15/1971 - " Better surgical techniques, combined with irradiation and chemotherapy have improved treatment of this pelvic cancer since 1944, but generally significant improvement in the treatment of malignancies has yet to be achieved. "
02/01/2012 - "Isolated pelvic perfusion with TNF-α compares favorably with historical data, as it was observed in limb perfusion and could provide a chance to translate its successful combination with chemotherapy into treatment of locally advanced pelvic cancers."
01/01/2012 - "The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. "
08/01/2004 - "Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers."
05/01/1985 - "Gluteal artery occlusion: intra-arterial chemotherapy of pelvic neoplasms."
11/01/2012 - "Subepithelial pelvic hematoma (Antopol Goldman lesion) is a rare condition that may clinical and radiologically simulate a renal or pelvic neoplasm and whose final diagnosis has been established after nephrectomy in most published cases. "
04/01/2011 - "Nephrectomy plus endoscopy-assisted intussusception ureterectomy is an oncologically safe alternative for renal pelvic cancer patients, which is possibly associated with less patient morbidity."
04/01/2011 - "We reviewed 181 consecutive patients with renal pelvic cancer who underwent open nephroureterectomy with complete bladder cuff removal (cuff removal group, n = 33), nephroureterectomy with incomplete cuff removal (orifice-remaining group, n = 39), and nephrectomy with intussusception ureterectomy (intussusception group, n = 109). "
04/01/2011 - "To assess long-term oncologic outcomes in patients with renal pelvic cancer who are receiving nephrectomy plus endoscopy-assisted intussusception ureterectomy. "
04/01/2011 - "Nephrectomy plus endoscopy-assisted intussusception ureterectomy for patients with renal pelvic cancer: long-term oncologic outcomes in comparison with nephroureterectomy plus bladder cuff removal."
11/01/1983 - "Low dose rate (LDR) neutron brachytherapy has been shown to be effective against cervical and advanced pelvic cancers; and produces 5 year cures without a high frequency of normal tissue complications. "
10/01/1990 - "[Interstitial brachytherapy in pelvic neoplasms]."
05/01/1985 - "Therapeutic dosimetry for Cf-252 neutron brachytherapy of pelvic cancer."
07/01/1983 - "This indicates that a variety of individualized arrangements for different clinical presentations can be used for brachytherapy of gynecological pelvic neoplasm."
01/19/2005 - "Pelvic external radiotherapy with or without brachytherapy plays an important role in the management of pelvic cancers. "
06/01/2013 - "Randomised controlled trials (RCT), controlled trials (CT) and case series in adult patients receiving radiotherapy for pelvic cancers employing nutritional interventions to reduce gastrointestinal toxicity were included. "
02/01/2013 - "However, prospective and clinical controlled trials all demonstrated a severe negative effect on sexual functioning in men and women following radiotherapy for a pelvic cancer. "
01/01/1995 - "From June 1992 to January 1993, 51 consecutive patients with pelvic cancers treated with radiotherapy alone, or surgery plus post-operative radiotherapy, were included in a study of the effectiveness of a false table-top (bellyboard) in displacing small bowel loops out of anteriorposterior (AP) and posterioranterior (PA) opposing pelvic fields. "
07/01/2015 - "The accuracy of radiotherapy can be highly increased with the use of IGRT in pelvic cancer."
11/01/2013 - "Pelvic radiation disease is one of the major complication after radiotherapy for pelvic cancers. "